Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin

Trial Profile

Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Botulinum-antitoxin (Primary)
  • Indications Botulism
  • Focus Adverse reactions
  • Sponsors Cangene Corporation
  • Most Recent Events

    • 04 Apr 2016 Planned End Date changed from 1 Apr 2018 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 04 Apr 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 24 Dec 2014 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top